ENANTA PHARMACEUTICALS, INC Research and Development Expense
ENANTA PHARMACEUTICALS, INC (ENTA) reported Research and Development Expense of $22.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC research and development expense for the quarter ending 2026-06-30 was $22.13M, a 18.68% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC research and development expense for the quarter ending 2026-03-31 was $19.44M, a 30.72% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC research and development expense for the quarter ending 2025-12-31 was $20.86M, a 24.58% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC research and development expense for the quarter ending 2025-09-30 was $23.81M, a 22.64% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC research and development expense for fiscal 2025 was $106.74M, a 18.81% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC research and development expense for fiscal 2024 was $131.48M, a 19.60% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC research and development expense for fiscal 2023 was $163.52M, a 0.61% decline from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC research and development expense for fiscal 2022 was $164.52M, a 5.51% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.13M 10-Q · filed 2026-08-12 | $41.57M derived: sum of 2 quarters · filed 2026-08-12 | $62.43M 10-Q · filed 2026-08-12 | $86.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $19.44M 10-Q · filed 2026-05-13 | $40.30M 10-Q · filed 2026-05-13 | $64.11M derived: sum of 3 quarters · filed 2026-05-13 | $91.32M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $20.86M 10-Q · filed 2026-02-11 | $44.67M derived: sum of 2 quarters · filed 2026-02-11 | $71.88M derived: sum of 3 quarters · filed 2026-08-12 | $99.94M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | $23.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $51.02M derived: sum of 2 quarters · filed 2026-08-12 | $79.08M derived: sum of 3 quarters · filed 2026-08-12 | $106.74M 10-K · filed 2025-11-19 |
| 2025-06-30 | $27.21M 10-Q · filed 2026-08-12 | $55.27M derived: sum of 2 quarters · filed 2026-08-12 | $82.93M 10-Q · filed 2026-08-12 | $113.71M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $28.07M 10-Q · filed 2026-05-13 | $55.72M 10-Q · filed 2026-05-13 | $86.50M derived: sum of 3 quarters · filed 2026-05-13 | $115.24M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $27.66M 10-Q · filed 2026-02-11 | $58.43M derived: sum of 2 quarters · filed 2026-02-11 | $87.18M derived: sum of 3 quarters · filed 2026-02-11 | $122.76M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $30.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $59.52M derived: sum of 2 quarters · filed 2025-11-19 | $95.11M derived: sum of 3 quarters · filed 2025-11-19 | $131.48M 10-K · filed 2025-11-19 |
| 2024-06-30 | $28.74M 10-Q · filed 2025-08-13 | $64.33M derived: sum of 2 quarters · filed 2025-08-13 | $100.70M 10-Q · filed 2025-08-13 | $136.87M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-03-31 | $35.59M 10-Q · filed 2025-05-14 | $71.96M 10-Q · filed 2025-05-14 | $108.12M derived: sum of 3 quarters · filed 2025-11-19 | $151.11M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-12-31 | $36.37M 10-Q · filed 2025-02-12 | $72.54M derived: sum of 2 quarters · filed 2025-11-19 | $115.53M derived: sum of 3 quarters · filed 2025-11-19 | $158.99M derived: sum of 4 quarters · filed 2025-11-19 |
| 2023-09-30 | $36.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $79.15M derived: sum of 2 quarters · filed 2025-11-19 | $122.62M derived: sum of 3 quarters · filed 2025-11-19 | $163.52M 10-K · filed 2025-11-19 |
| 2023-06-30 | $42.99M 10-Q · filed 2024-08-07 | $86.45M derived: sum of 2 quarters · filed 2024-08-07 | $127.36M 10-Q · filed 2024-08-07 | $162.15M derived: sum of 4 quarters · filed 2024-11-27 |
| 2023-03-31 | $43.47M 10-Q · filed 2024-05-08 | $84.37M 10-Q · filed 2024-05-08 | $119.17M derived: sum of 3 quarters · filed 2024-11-27 | $158.26M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-12-31 | $40.90M 10-Q · filed 2024-02-08 | $75.70M derived: sum of 2 quarters · filed 2024-11-27 | $114.79M derived: sum of 3 quarters · filed 2024-11-27 | $156.88M derived: sum of 4 quarters · filed 2024-11-27 |
| 2022-09-30 | $34.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27 | $73.89M derived: sum of 2 quarters · filed 2024-11-27 | $115.97M derived: sum of 3 quarters · filed 2024-11-27 | $164.52M 10-K · filed 2024-11-27 |
| 2022-06-30 | $39.09M 10-Q · filed 2023-08-08 | $81.18M derived: sum of 2 quarters · filed 2023-08-08 | $129.73M 10-Q · filed 2023-08-08 | $178.67M derived: sum of 4 quarters · filed 2023-11-22 |
| 2022-03-31 | $42.09M 10-Q · filed 2023-05-09 | $90.64M 10-Q · filed 2023-05-09 | $139.58M derived: sum of 3 quarters · filed 2023-11-22 | $186.58M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-12-31 | $48.55M 10-Q · filed 2023-02-08 | $97.50M derived: sum of 2 quarters · filed 2023-11-22 | $144.49M derived: sum of 3 quarters · filed 2023-11-22 | $186.00M derived: sum of 4 quarters · filed 2023-11-22 |
| 2021-09-30 | $48.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-22 | $95.94M derived: sum of 2 quarters · filed 2023-11-22 | $137.45M derived: sum of 3 quarters · filed 2023-11-22 | $174.11M 10-K · filed 2023-11-22 |
| 2021-06-30 | $46.99M 10-Q · filed 2022-08-08 | $88.50M derived: sum of 2 quarters · filed 2022-08-08 | $125.17M 10-Q · filed 2022-08-08 | $161.85M derived: sum of 4 quarters · filed 2022-11-23 |
| 2021-03-31 | $41.51M 10-Q · filed 2022-05-09 | $78.17M 10-Q · filed 2022-05-09 | $114.86M derived: sum of 3 quarters · filed 2022-11-23 | $149.54M derived: sum of 4 quarters · filed 2022-11-23 |
| 2020-12-31 | $36.66M 10-Q · filed 2022-02-10 | $73.35M derived: sum of 2 quarters · filed 2022-11-23 | $108.03M derived: sum of 3 quarters · filed 2022-11-23 | $140.64M derived: sum of 4 quarters · filed 2022-11-23 |
| 2020-09-30 | $36.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23 | $71.37M derived: sum of 2 quarters · filed 2022-11-23 | $103.98M derived: sum of 3 quarters · filed 2022-11-23 | $136.76M 10-K · filed 2022-11-23 |
| 2020-06-30 | $34.68M 10-Q · filed 2021-08-09 | $67.29M derived: sum of 2 quarters · filed 2021-08-09 | $100.07M 10-Q · filed 2021-08-09 | $138.79M derived: sum of 4 quarters · filed 2021-11-24 |
| 2020-03-31 | $32.61M 10-Q · filed 2021-05-10 | $65.39M 10-Q · filed 2021-05-10 | $104.11M derived: sum of 3 quarters · filed 2021-11-24 | $138.57M derived: sum of 4 quarters · filed 2021-11-24 |
| 2019-12-31 | $32.78M 10-Q · filed 2021-02-09 | $71.50M derived: sum of 2 quarters · filed 2021-11-24 | $105.96M derived: sum of 3 quarters · filed 2021-11-24 | $140.11M derived: sum of 4 quarters · filed 2021-11-24 |
| 2019-09-30 | $38.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $73.18M derived: sum of 2 quarters · filed 2021-11-24 | $107.33M derived: sum of 3 quarters · filed 2021-11-24 | $142.21M 10-K · filed 2021-11-24 |
| 2019-06-30 | $34.46M 10-Q · filed 2020-08-10 | $68.62M derived: sum of 2 quarters · filed 2020-08-10 | $103.49M 10-Q · filed 2020-08-10 | $130.42M derived: sum of 4 quarters · filed 2020-11-25 |
| 2019-03-31 | $34.16M 10-Q · filed 2020-05-11 | $69.03M 10-Q · filed 2020-05-11 | $95.96M derived: sum of 3 quarters · filed 2020-11-25 | $124.44M derived: sum of 4 quarters · filed 2020-11-25 |
| 2018-12-31 | $34.88M 10-Q · filed 2020-02-10 | $61.80M derived: sum of 2 quarters · filed 2020-11-25 | $90.29M derived: sum of 3 quarters · filed 2020-11-25 | $111.77M derived: sum of 4 quarters · filed 2020-11-25 |
| 2018-09-30 | $26.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-25 | $55.41M derived: sum of 2 quarters · filed 2020-11-25 | $76.89M derived: sum of 3 quarters · filed 2020-11-25 | $94.86M 10-K · filed 2020-11-25 |
| 2018-06-30 | $28.49M 10-Q · filed 2019-08-09 | $49.97M derived: sum of 2 quarters · filed 2019-08-09 | $67.93M 10-Q · filed 2019-08-09 | $84.45M derived: sum of 4 quarters · filed 2019-11-27 |
| 2018-03-31 | $21.48M 10-Q · filed 2019-05-10 | $39.45M 10-Q · filed 2019-05-10 | $55.96M derived: sum of 3 quarters · filed 2019-11-27 | $71.37M derived: sum of 4 quarters · filed 2019-11-27 |
| 2017-12-31 | $17.96M 10-Q · filed 2019-02-08 | $34.48M derived: sum of 2 quarters · filed 2019-11-27 | $49.88M derived: sum of 3 quarters · filed 2019-11-27 | $62.89M derived: sum of 4 quarters · filed 2019-11-27 |
| 2017-09-30 | $16.51M derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27 | $31.92M derived: sum of 2 quarters · filed 2019-11-27 | $44.92M derived: sum of 3 quarters · filed 2019-11-27 | $57.45M 10-K · filed 2019-11-27 |
| 2017-06-30 | $15.41M 10-Q · filed 2018-08-09 | $28.41M derived: sum of 2 quarters · filed 2018-08-09 | $40.94M 10-Q · filed 2018-08-09 | $52.44M derived: sum of 4 quarters · filed 2018-11-29 |
| 2017-03-31 | $13.00M 10-Q · filed 2018-05-10 | $25.53M 10-Q · filed 2018-05-10 | $37.03M derived: sum of 3 quarters · filed 2018-11-29 | $47.81M derived: sum of 4 quarters · filed 2018-11-29 |
| 2016-12-31 | $12.53M 10-Q · filed 2018-02-09 | $24.03M derived: sum of 2 quarters · filed 2018-11-29 | $34.81M derived: sum of 3 quarters · filed 2018-11-29 | $43.95M derived: sum of 4 quarters · filed 2018-11-29 |
| 2016-09-30 | $11.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | $22.29M derived: sum of 2 quarters · filed 2018-11-29 | $31.43M derived: sum of 3 quarters · filed 2018-11-29 | $40.46M 10-K · filed 2018-11-29 |
| 2016-06-30 | $10.79M 10-Q · filed 2017-08-09 | $19.93M derived: sum of 2 quarters · filed 2017-08-09 | $28.96M 10-Q · filed 2017-08-09 | $36.01M derived: sum of 4 quarters · filed 2017-12-11 |
| 2016-03-31 | $9.14M 10-Q · filed 2017-05-10 | $18.18M 10-Q · filed 2017-05-10 | $25.23M derived: sum of 3 quarters · filed 2017-12-11 | $31.48M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-12-31 | $9.03M 10-Q · filed 2017-02-09 | $16.08M derived: sum of 2 quarters · filed 2017-12-11 | $22.34M derived: sum of 3 quarters · filed 2017-12-11 | $27.70M derived: sum of 4 quarters · filed 2017-12-11 |
| 2015-09-30 | $7.05M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11 | $13.30M derived: sum of 2 quarters · filed 2017-12-11 | $18.67M derived: sum of 3 quarters · filed 2017-12-11 | $23.19M 10-K · filed 2017-12-11 |
| 2015-06-30 | $6.25M 10-Q · filed 2016-08-09 | $11.62M derived: sum of 2 quarters · filed 2016-08-09 | $16.14M 10-Q · filed 2016-08-09 | $21.34M derived: sum of 4 quarters · filed 2016-12-09 |
| 2015-03-31 | $5.37M 10-Q · filed 2016-05-10 | $9.89M 10-Q · filed 2016-05-10 | $15.09M derived: sum of 3 quarters · filed 2016-12-09 | $19.64M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-12-31 | $4.52M 10-Q · filed 2016-02-09 | $9.72M derived: sum of 2 quarters · filed 2016-12-09 | $14.27M derived: sum of 3 quarters · filed 2016-12-09 | $19.00M derived: sum of 4 quarters · filed 2016-12-09 |
| 2014-09-30 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09 | $9.76M derived: sum of 2 quarters · filed 2016-12-09 | $14.48M derived: sum of 3 quarters · filed 2016-12-09 | $18.74M 10-K · filed 2016-12-09 |
| 2014-06-30 | $4.55M 10-Q · filed 2015-08-10 | $9.28M derived: sum of 2 quarters · filed 2015-08-10 | $13.54M 10-Q · filed 2015-08-10 | $17.84M derived: sum of 4 quarters · filed 2015-12-11 |
| 2014-03-31 | $4.72M 10-Q · filed 2015-05-08 | $8.98M 10-Q · filed 2015-05-08 | $13.29M derived: sum of 3 quarters · filed 2015-12-11 | $17.32M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-12-31 | $4.26M 10-Q · filed 2015-02-06 | $8.56M derived: sum of 2 quarters · filed 2015-12-11 | $12.60M derived: sum of 3 quarters · filed 2015-12-11 | $16.31M derived: sum of 4 quarters · filed 2015-12-11 |
| 2013-09-30 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11 | $8.34M derived: sum of 2 quarters · filed 2015-12-11 | $12.04M derived: sum of 3 quarters · filed 2015-12-11 | $16.84M 10-K · filed 2015-12-11 |
| 2013-06-30 | $4.04M 10-Q · filed 2014-08-12 | $7.74M derived: sum of 2 quarters · filed 2014-08-12 | $12.54M 10-Q · filed 2014-08-12 | $16.80M derived: sum of 4 quarters · filed 2014-12-11 |
| 2013-03-31 | $3.70M 10-Q · filed 2014-05-12 | $8.50M 10-Q · filed 2014-05-12 | $12.76M derived: sum of 3 quarters · filed 2014-12-11 | $17.68M derived: sum of 4 quarters · filed 2014-12-11 |
| 2012-12-31 | $4.80M 10-Q · filed 2014-02-13 | $9.05M derived: sum of 2 quarters · filed 2014-12-11 | $13.98M derived: sum of 3 quarters · filed 2014-12-11 | $17.24M derived: sum of 4 quarters · filed 2014-12-11 |
| 2012-09-30 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11 | $9.18M derived: sum of 2 quarters · filed 2014-12-11 | $12.44M derived: sum of 3 quarters · filed 2014-12-11 | $15.12M 10-K · filed 2014-12-11 |
| 2012-06-30 | $4.92M 10-Q · filed 2013-08-12 | $8.19M derived: sum of 2 quarters · filed 2013-08-12 | $10.86M 10-Q · filed 2013-08-12 | |
| 2012-03-31 | $3.26M 10-Q · filed 2013-05-15 | $5.93M 10-Q · filed 2013-05-15 | ||
| 2011-09-30 | $11.55M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |